Gaurav Chattree
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gaurav Chattree has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Yanping Zhang
CNC Program Stanford University Stanford California USA
3 shared publicationsFatih Dinc
CNC Program Stanford University Stanford California USA
2 shared publicationsJane Li
CNC Program Stanford University Stanford California USA
2 shared publications- Mark J. Schnitzer
CNC Program, Stanford University, Stanford, CA 94305, USA
2 shared publications - Radosław Chrapkiewicz
CNC Program, Stanford University, Stanford, CA 94305, USA
2 shared publications - Ali Cetin
Allen Institute for Brain Science
1 shared publication
Latest Publications
- 22 July 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (10) , 2723-2736
Amantadine Modulates Action‐Specific Neural Ensembles in Hypokinetic and Hyperkinetic Conditions
Background: In the classical model of basal ganglia circuitry, striatal spiny projection neurons of the direct and indirect pathways (dSPNs, iSPNs) promote and suppress movement, respectively, and exhibit unbalanced activity levels during hypokinetic or hyperkinetic conditions. Most therapies for these conditions are thought to work by rebalancing the relative activity of dSPNs and iSPNs toward normal levels. However, the mechanism of amantadine, which uniquely improves both hypokinetic and hyperkinetic conditions, is poorly understood. Objective: Our aim was to determine whether amantadine restores motor function by normalizing the balance of dSPN and iSPN activity or through a distinct mechanism. Methods: We used dual‐color two‐photon Ca 2+ imaging in the 6‐hydroxydopamine (6‐OHDA) mouse model of Parkinson's disease to concurrently monitor dSPN and iSPN dynamics across healthy, hypokinetic (parkinsonian), and hyperkinetic (dyskinetic) conditions. Results: We evaluated both dSPN/iSPN activity balance and action‐specific neural ensemble activity in the dorsolateral striatum. In hypokinetic conditions, levodopa rescued the dSPN/iSPN imbalance but failed to restore the disrupted activity of the locomotion‐specific ensemble. Conversely, amantadine improved locomotion‐specific ensemble activity without normalizing the dSPN/iSPN imbalance. In hyperkinetic conditions, forelimb dyskinesias were characterized by neural activity patterns distinct from those encoding locomotion. Amantadine selectively suppressed the resting activity of forelimb dyskinesia ensembles without affecting locomotion‐coding ensembles or restoring pathway balance. Conclusions: Levodopa and amantadine may act through distinct mechanisms, with levodopa normalizing pathway balance and amantadine modulating action‐specific neural ensembles. These findings support the importance of action‐coding disruptions during hypokinetic and hyperkinetic conditions and suggest that correcting them can restore motor function. © 2026 International Parkinson and Movement Disorder Society.
- 22 July 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (10) , 2723-2736
Amantadine Modulates Action‐Specific Neural Ensembles in Hypokinetic and Hyperkinetic Conditions
Background: In the classical model of basal ganglia circuitry, striatal spiny projection neurons of the direct and indirect pathways (dSPNs, iSPNs) promote and suppress movement, respectively, and exhibit unbalanced activity levels during hypokinetic or hyperkinetic conditions. Most therapies for these conditions are thought to work by rebalancing the relative activity of dSPNs and iSPNs toward normal levels. However, the mechanism of amantadine, which uniquely improves both hypokinetic and hyperkinetic conditions, is poorly understood. Objective: Our aim was to determine whether amantadine restores motor function by normalizing the balance of dSPN and iSPN activity or through a distinct mechanism. Methods: We used dual‐color two‐photon Ca 2+ imaging in the 6‐hydroxydopamine (6‐OHDA) mouse model of Parkinson's disease to concurrently monitor dSPN and iSPN dynamics across healthy, hypokinetic (parkinsonian), and hyperkinetic (dyskinetic) conditions. Results: We evaluated both dSPN/iSPN activity balance and action‐specific neural ensemble activity in the dorsolateral striatum. In hypokinetic conditions, levodopa rescued the dSPN/iSPN imbalance but failed to restore the disrupted activity of the locomotion‐specific ensemble. Conversely, amantadine improved locomotion‐specific ensemble activity without normalizing the dSPN/iSPN imbalance. In hyperkinetic conditions, forelimb dyskinesias were characterized by neural activity patterns distinct from those encoding locomotion. Amantadine selectively suppressed the resting activity of forelimb dyskinesia ensembles without affecting locomotion‐coding ensembles or restoring pathway balance. Conclusions: Levodopa and amantadine may act through distinct mechanisms, with levodopa normalizing pathway balance and amantadine modulating action‐specific neural ensembles. These findings support the importance of action‐coding disruptions during hypokinetic and hyperkinetic conditions and suggest that correcting them can restore motor function. © 2026 International Parkinson and Movement Disorder Society.
- Open Access
Multimodal alignments of in vivo imaging and spatial biology datasets at cellular resolution
Parallel revolutions in intravital microscopy and spatial biology techniques have respectively enabled large-scale recordings of cellular dynamics in live animals and multi-dimensional molecular profiling at single-cell resolution. However, due to the challenges of aligning data from different modalities at cellular resolution, these two transformational approaches have generally been applied on separate biological samples, stymying the ability to link activity patterns and molecular attributes in the same exact cells. To enable routine, multimodal investigations of cells’ in vivo dynamics and molecular content, we created TRU-FACT (Total Registration Under Functional Activity, Connectivity, and Transcriptomics), a broadly applicable experimental and computational pipeline for registering large populations of individual cells across intravital imaging and spatial biology datasets. The pipeline combines three key innovations: an optomechanical tissue handling and alignment method to parallelize specimen planes, a graph-theoretic method to register individual cells based on their geometric relationships to neighboring cells, and a statistical framework that provides for each cell an a posteriori probability of correct registration. We validated TRU-FACT with several preparations for imaging neural Ca 2+ activity in cortical and deep brain areas in head-fixed and freely behaving mice, RNA-barcode-expressing viruses for labeling neural projections, and low- and high-plex spatial transcriptomic methods. In mice performing a skilled reaching task, TRU-FACT alignments revealed the movement-related signaling patterns of intratelencephalic, extratelencephalic, and striatum-, superior colliculus-, and thalamus-projecting motor cortical neurons. Overall, TRU-FACT constitutes a scalable, multimodal discovery platform that is applicable to diverse tissue-types and spatial biology techniques, thereby enabling multiscale analyses of many complex biological systems.
Open AccessMultimodal alignments of in vivo imaging and spatial biology datasets at cellular resolution
Parallel revolutions in intravital microscopy and spatial biology techniques have respectively enabled large-scale recordings of cellular dynamics in live animals and multi-dimensional molecular profiling at single-cell resolution. However, due to the challenges of aligning data from different modalities at cellular resolution, these two transformational approaches have generally been applied on separate biological samples, stymying the ability to link activity patterns and molecular attributes in the same exact cells. To enable routine, multimodal investigations of cells’ in vivo dynamics and molecular content, we created TRU-FACT (Total Registration Under Functional Activity, Connectivity, and Transcriptomics), a broadly applicable experimental and computational pipeline for registering large populations of individual cells across intravital imaging and spatial biology datasets. The pipeline combines three key innovations: an optomechanical tissue handling and alignment method to parallelize specimen planes, a graph-theoretic method to register individual cells based on their geometric relationships to neighboring cells, and a statistical framework that provides for each cell an a posteriori probability of correct registration. We validated TRU-FACT with several preparations for imaging neural Ca 2+ activity in cortical and deep brain areas in head-fixed and freely behaving mice, RNA-barcode-expressing viruses for labeling neural projections, and low- and high-plex spatial transcriptomic methods. In mice performing a skilled reaching task, TRU-FACT alignments revealed the movement-related signaling patterns of intratelencephalic, extratelencephalic, and striatum-, superior colliculus-, and thalamus-projecting motor cortical neurons. Overall, TRU-FACT constitutes a scalable, multimodal discovery platform that is applicable to diverse tissue-types and spatial biology techniques, thereby enabling multiscale analyses of many complex biological systems.
- Open Access
Amantadine modulates action-specific neural ensembles in hypokinetic and hyperkinetic conditions
Background: In the classical model of basal ganglia circuitry, striatal spiny projection neurons of the direct and indirect pathways (dSPNs, iSPNs) promote and suppress movement, respectively, and exhibit unbalanced activity levels during hypokinetic or hyperkinetic conditions. Most therapies for these conditions are thought to work by rebalancing the relative activity of dSPNs and iSPNs towards normal levels. However, the mechanism of amantadine, which uniquely improves both hypokinetic and hyperkinetic conditions, is poorly understood. Objective: To determine whether amantadine restores motor function by normalizing the balance of dSPN and iSPN activity or through a distinct mechanism. Methods: We used dual-color two-photon Ca 2+ imaging in the 6-OHDA mouse model of Parkinson’s disease to concurrently monitor dSPN and iSPN dynamics across healthy, hypokinetic (parkinsonian), and hyperkinetic (dyskinetic) conditions. Results: We evaluated both dSPN/iSPN activity balance and action-specific neural ensemble activity in the dorsolateral striatum. In hypokinetic conditions, L-DOPA rescued the dSPN/iSPN imbalance but failed to restore the disrupted activity of the locomotion-specific ensemble. Conversely, amantadine improved locomotion-specific ensemble activity without normalizing the dSPN/iSPN imbalance. In hyperkinetic conditions, forelimb dyskinesias were characterized by neural activity patterns distinct from those encoding locomotion. Amantadine selectively suppressed the resting activity of forelimb dyskinesia ensembles without affecting locomotion-coding ensembles or restoring pathway balance. Conclusions: L-DOPA and amantadine may act through distinct mechanisms, with L-DOPA normalizing pathway balance and amantadine modulating action-specific neural ensembles. These findings support the importance of action-coding disruptions during hypokinetic and hyperkinetic conditions and suggest that correcting them can restore motor function.
Open AccessAmantadine modulates action-specific neural ensembles in hypokinetic and hyperkinetic conditions
Background: In the classical model of basal ganglia circuitry, striatal spiny projection neurons of the direct and indirect pathways (dSPNs, iSPNs) promote and suppress movement, respectively, and exhibit unbalanced activity levels during hypokinetic or hyperkinetic conditions. Most therapies for these conditions are thought to work by rebalancing the relative activity of dSPNs and iSPNs towards normal levels. However, the mechanism of amantadine, which uniquely improves both hypokinetic and hyperkinetic conditions, is poorly understood. Objective: To determine whether amantadine restores motor function by normalizing the balance of dSPN and iSPN activity or through a distinct mechanism. Methods: We used dual-color two-photon Ca 2+ imaging in the 6-OHDA mouse model of Parkinson’s disease to concurrently monitor dSPN and iSPN dynamics across healthy, hypokinetic (parkinsonian), and hyperkinetic (dyskinetic) conditions. Results: We evaluated both dSPN/iSPN activity balance and action-specific neural ensemble activity in the dorsolateral striatum. In hypokinetic conditions, L-DOPA rescued the dSPN/iSPN imbalance but failed to restore the disrupted activity of the locomotion-specific ensemble. Conversely, amantadine improved locomotion-specific ensemble activity without normalizing the dSPN/iSPN imbalance. In hyperkinetic conditions, forelimb dyskinesias were characterized by neural activity patterns distinct from those encoding locomotion. Amantadine selectively suppressed the resting activity of forelimb dyskinesia ensembles without affecting locomotion-coding ensembles or restoring pathway balance. Conclusions: L-DOPA and amantadine may act through distinct mechanisms, with L-DOPA normalizing pathway balance and amantadine modulating action-specific neural ensembles. These findings support the importance of action-coding disruptions during hypokinetic and hyperkinetic conditions and suggest that correcting them can restore motor function.